1
|
Lira RLDS, Nogueira FAB, Campos RDFPDC, Ferreira DRM, Roxo PLBT, de Azevedo CCS, Gimenes ECM, Bastos RLC, Nascimento CEC, Nunes FDO, Marques MCP, Campos CDL, Martinez CG, Zagmignan A, Silva LCN, Ribeiro RM, de Azevedo dos Santos APS, Carvalho RC, de Sousa EM. Mycobacterium abscessus subsp. massiliense: Biofilm Formation, Host Immune Response, and Therapeutic Strategies. Microorganisms 2025; 13:447. [PMID: 40005812 PMCID: PMC11858063 DOI: 10.3390/microorganisms13020447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2025] [Revised: 02/08/2025] [Accepted: 02/11/2025] [Indexed: 02/27/2025] Open
Abstract
Infection by Mycobacterium abscessus subsp. massiliense poses a growing public health threat, especially to immunocompromised individuals. The pathogenicity of this mycobacterium is directly linked to its ability to form biofilms, complex structures that confer resistance to antibiotics and the host immune response. The extracellular matrix of the biofilm acts as a physical barrier, hindering the penetration of drugs and the action of the immune system, while also inducing a slow-growth state that reduces susceptibility to antibiotics. Current therapies, which involve prolonged use of multiple antibiotics, are often ineffective and cause significant side effects. Therefore, it is essential to explore new strategies targeting bacterial resistance and biofilm destruction. This narrative review explores the biofilm-forming capacity of Mycobacterium abscessus subsp. massiliense and the potential of novel therapeutic strategies. Promising approaches include inhibiting biofilm formation, developing drugs with improved penetration of the extracellular matrix, combination therapies with agents that destabilize the biofilm structure, and modulating the host immune response. Investing in research and development of new therapeutic strategies is essential to combat this resistant bacterium and improve patient outcomes.
Collapse
Affiliation(s)
- Roseane Lustosa de Santana Lira
- Graduate Program in Health Sciences, Federal University of Maranhão—UFMA, São Luís 65080-805, Brazil; (R.L.d.S.L.); (C.E.C.N.); (F.D.O.N.); (M.C.P.M.); (C.D.L.C.); (R.M.R.); (A.P.S.d.A.d.S.); (R.C.C.)
| | - Flávio Augusto Barros Nogueira
- Graduate Program in Biodiversity and Biotechnology, Amazônia—BIONORTE, Federal University of Maranhão—UFMA, São Luís 65080-805, Brazil; (F.A.B.N.); (A.Z.)
| | | | - Dayenne Regina Mota Ferreira
- Graduate Program in Biosciences Applied to Health, CEUMA University—UNICEUMA, São Luís 65075-120, Brazil; (R.d.F.P.d.C.C.); (D.R.M.F.); (C.G.M.); (L.C.N.S.)
| | - Pedro Lucas Brito Tromps Roxo
- Undergraduate in Medicine, CEUMA University—UNICEUMA, São Luís 65075-120, Brazil; (P.L.B.T.R.); (C.C.S.d.A.); (E.C.M.G.); (R.L.C.B.)
| | - Caio César Santana de Azevedo
- Undergraduate in Medicine, CEUMA University—UNICEUMA, São Luís 65075-120, Brazil; (P.L.B.T.R.); (C.C.S.d.A.); (E.C.M.G.); (R.L.C.B.)
| | - Eleonôra Costa Monteiro Gimenes
- Undergraduate in Medicine, CEUMA University—UNICEUMA, São Luís 65075-120, Brazil; (P.L.B.T.R.); (C.C.S.d.A.); (E.C.M.G.); (R.L.C.B.)
| | - Ruan Lucas Costa Bastos
- Undergraduate in Medicine, CEUMA University—UNICEUMA, São Luís 65075-120, Brazil; (P.L.B.T.R.); (C.C.S.d.A.); (E.C.M.G.); (R.L.C.B.)
| | - Camila Evangelista Carnib Nascimento
- Graduate Program in Health Sciences, Federal University of Maranhão—UFMA, São Luís 65080-805, Brazil; (R.L.d.S.L.); (C.E.C.N.); (F.D.O.N.); (M.C.P.M.); (C.D.L.C.); (R.M.R.); (A.P.S.d.A.d.S.); (R.C.C.)
| | - Flávia Danyelle Oliveira Nunes
- Graduate Program in Health Sciences, Federal University of Maranhão—UFMA, São Luís 65080-805, Brazil; (R.L.d.S.L.); (C.E.C.N.); (F.D.O.N.); (M.C.P.M.); (C.D.L.C.); (R.M.R.); (A.P.S.d.A.d.S.); (R.C.C.)
| | - Mayane Cristina Pereira Marques
- Graduate Program in Health Sciences, Federal University of Maranhão—UFMA, São Luís 65080-805, Brazil; (R.L.d.S.L.); (C.E.C.N.); (F.D.O.N.); (M.C.P.M.); (C.D.L.C.); (R.M.R.); (A.P.S.d.A.d.S.); (R.C.C.)
| | - Carmem Duarte Lima Campos
- Graduate Program in Health Sciences, Federal University of Maranhão—UFMA, São Luís 65080-805, Brazil; (R.L.d.S.L.); (C.E.C.N.); (F.D.O.N.); (M.C.P.M.); (C.D.L.C.); (R.M.R.); (A.P.S.d.A.d.S.); (R.C.C.)
| | - Camila Guerra Martinez
- Graduate Program in Biosciences Applied to Health, CEUMA University—UNICEUMA, São Luís 65075-120, Brazil; (R.d.F.P.d.C.C.); (D.R.M.F.); (C.G.M.); (L.C.N.S.)
| | - Adrielle Zagmignan
- Graduate Program in Biodiversity and Biotechnology, Amazônia—BIONORTE, Federal University of Maranhão—UFMA, São Luís 65080-805, Brazil; (F.A.B.N.); (A.Z.)
- Graduate Program in Biosciences Applied to Health, CEUMA University—UNICEUMA, São Luís 65075-120, Brazil; (R.d.F.P.d.C.C.); (D.R.M.F.); (C.G.M.); (L.C.N.S.)
| | - Luís Cláudio Nascimento Silva
- Graduate Program in Biosciences Applied to Health, CEUMA University—UNICEUMA, São Luís 65075-120, Brazil; (R.d.F.P.d.C.C.); (D.R.M.F.); (C.G.M.); (L.C.N.S.)
| | - Rachel Melo Ribeiro
- Graduate Program in Health Sciences, Federal University of Maranhão—UFMA, São Luís 65080-805, Brazil; (R.L.d.S.L.); (C.E.C.N.); (F.D.O.N.); (M.C.P.M.); (C.D.L.C.); (R.M.R.); (A.P.S.d.A.d.S.); (R.C.C.)
| | - Ana Paula Silva de Azevedo dos Santos
- Graduate Program in Health Sciences, Federal University of Maranhão—UFMA, São Luís 65080-805, Brazil; (R.L.d.S.L.); (C.E.C.N.); (F.D.O.N.); (M.C.P.M.); (C.D.L.C.); (R.M.R.); (A.P.S.d.A.d.S.); (R.C.C.)
| | - Rafael Cardoso Carvalho
- Graduate Program in Health Sciences, Federal University of Maranhão—UFMA, São Luís 65080-805, Brazil; (R.L.d.S.L.); (C.E.C.N.); (F.D.O.N.); (M.C.P.M.); (C.D.L.C.); (R.M.R.); (A.P.S.d.A.d.S.); (R.C.C.)
| | - Eduardo Martins de Sousa
- Graduate Program in Health Sciences, Federal University of Maranhão—UFMA, São Luís 65080-805, Brazil; (R.L.d.S.L.); (C.E.C.N.); (F.D.O.N.); (M.C.P.M.); (C.D.L.C.); (R.M.R.); (A.P.S.d.A.d.S.); (R.C.C.)
- Graduate Program in Biodiversity and Biotechnology, Amazônia—BIONORTE, Federal University of Maranhão—UFMA, São Luís 65080-805, Brazil; (F.A.B.N.); (A.Z.)
- Graduate Program in Biosciences Applied to Health, CEUMA University—UNICEUMA, São Luís 65075-120, Brazil; (R.d.F.P.d.C.C.); (D.R.M.F.); (C.G.M.); (L.C.N.S.)
| |
Collapse
|
2
|
Ethyl Acetate Fraction of Bixa orellana and Its Component Ellagic Acid Exert Antibacterial and Anti-Inflammatory Properties against Mycobacterium abscessus subsp. massiliense. Antibiotics (Basel) 2022; 11:antibiotics11060817. [PMID: 35740223 PMCID: PMC9220277 DOI: 10.3390/antibiotics11060817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2022] [Revised: 06/13/2022] [Accepted: 06/15/2022] [Indexed: 11/16/2022] Open
Abstract
Mycobacterium abscessus subsp. massiliense (Mabs) causes chronic infections, which has led to the need for new antimycobacterial agents. In this study, we investigated the antimycobacterial and anti-inflammatory activities of the ethyl acetate fraction of Bixa orellana leaves (BoEA) and ellagic acid (ElAc). In silico analysis predicted that ElAc had low toxicity, was not mutagenic or carcinogenic, and had antimicrobial and anti-inflammatory activities. Apparently, ElAc can interact with COX2 and Dihydrofolate reductase (DHFR) enzymes, which could explain both activities. In vitro analysis showed that BoEA and ElAc exerted antimicrobial activity against Mabs (minimum inhibitory concentration of 1.56, 1.56 mg/mL and bactericidal concentration of 6.25, 3.12 mg/mL, respectively. Clarithromycin showed MIC and MBC of 1 and 6 µg/mL). Treatment with BoEA or ElAc increased survival of Tenebrio molitor larvae after lethal infection with Mabs and reduced carrageenan-induced paw edema in mice, around 40% of edema volume after the fourth hour, similarly to diclofenac. In conclusion, BoEA and ElAc exert antimicrobial effects against Mabs and have anti-inflammatory effects, making them potential sources of antimycobacterial drugs. The biological activities of ElAc may be due to its high binding affinities predicted for COX2 and DHFR enzymes.
Collapse
|
3
|
Sirichoat A, Kham-Ngam I, Kaewprasert O, Ananta P, Wisetsai A, Lekphrom R, Faksri K. Assessment of antimycobacterial activities of pure compounds extracted from Thai medicinal plants against clarithromycin-resistant Mycobacterium abscessus. PeerJ 2021; 9:e12391. [PMID: 34760385 PMCID: PMC8555507 DOI: 10.7717/peerj.12391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2021] [Accepted: 10/05/2021] [Indexed: 11/30/2022] Open
Abstract
Background Infection with Mycobacterium abscessus is usually chronic and is associated with clarithromycin resistance. Increasing drug resistance is a major public-health problem and has led to the search for new antimycobacterial agents. We evaluated the antimycobacterial activity, toxicity, and synergistic effects of several plant secondary metabolites against M. abscessus. Methods Twenty-three compounds were evaluated for antimycobacterial activity against thirty M. abscessus clinical isolates by broth microdilution to determine their minimum inhibitory concentration (MIC) values. Toxicity was evaluated using red and white blood cells (RBCs and WBCs). The compounds were used in combination with clarithromycin to investigate the possibility of synergistic activity. Results Five out of twenty-three compounds (RL008, RL009, RL011, RL012 and RL013) exhibited interesting antimycobacterial activity against M. abscessus, with MIC values ranging from <1 to >128 μg/mL. These extracts did not induce hemolytic effect on RBCs and displayed low toxicity against WBCs. The five least-toxic compounds were tested for synergism with clarithromycin against seven isolates with inducible clarithromycin resistance and seven with acquired clarithromycin resistance. The best synergistic results against these isolates were observed for RL008 and RL009 (8/14 isolates; 57%). Conclusions This study demonstrated antimycobacterial and synergistic activities of pure compounds extracted from medicinal plants against clarithromycin-resistant M. abscessus. This synergistic action, together with clarithromycin, may be effective for treating infections and should be further studied for the development of novel antimicrobial agents.
Collapse
Affiliation(s)
- Auttawit Sirichoat
- Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.,Research and Diagnostic Center for Emerging Infectious Diseases, Khon Kaen University, Khon Kaen, Thailand
| | - Irin Kham-Ngam
- Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.,Research and Diagnostic Center for Emerging Infectious Diseases, Khon Kaen University, Khon Kaen, Thailand
| | - Orawee Kaewprasert
- Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.,Research and Diagnostic Center for Emerging Infectious Diseases, Khon Kaen University, Khon Kaen, Thailand
| | - Pimjai Ananta
- Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.,Clinical Laboratory Unit, Srinagarind Hospital, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
| | - Awat Wisetsai
- Natural Products Research Unit, Department of Chemistry, and Center for Innovation in Chemistry, Faculty of Science, Khon Kaen University, Khon Kaen, Thailand
| | - Ratsami Lekphrom
- Natural Products Research Unit, Department of Chemistry, and Center for Innovation in Chemistry, Faculty of Science, Khon Kaen University, Khon Kaen, Thailand
| | - Kiatichai Faksri
- Department of Microbiology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.,Research and Diagnostic Center for Emerging Infectious Diseases, Khon Kaen University, Khon Kaen, Thailand
| |
Collapse
|
4
|
Nascimento LDES, Nicolau RA, Maia Filho ALM, Nascimento KFES, Santos JZLV, Sousa RCD, Carvalho LFM, Viana VGF. Effect of low intensity photobiomodulation associated with norbixin-based poly (hydroxybutyrate) membrane on post-tenotomy tendon repair. In vivo study. Acta Cir Bras 2020; 35:e202000303. [PMID: 32490900 PMCID: PMC7357841 DOI: 10.1590/s0102-865020200030000003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2019] [Accepted: 02/15/2020] [Indexed: 12/29/2022] Open
Abstract
Purpose: To evaluate the in vivo response of photobiomodulation therapy associated with norbixin-based poly(hydroxybutyrate) membrane (PHB) in tenotomized calcaneal tendon. Methods: Thirty rats were randomly allocated to six groups (n=5 each): LED groups (L1, L2 and L3) and membrane + LED groups (ML1, ML2 and ML3). The right calcaneal tendons of all animals were sectioned transversely and were irradiated with LED daily, one hour after surgery every 24 hours, until the day of euthanasia. At the end of the experiments the tendons were removed for histological analysis. Results: The histological analysis showed a significant reduction in inflammatory cells in the ML1, ML2 and ML3 groups (p=0.0056, p=0.0018 and p<0.0001, respectively) compared to those in the LED group. There was greater proliferation of fibroblasts in the ML1 (p<0.0001) and L3 (p<0.0001) groups. A higher concentration of type I collagen was also observed in the ML1 group (p=0.0043) replacing type III collagen. Conclusion: Photobiomodulation in association with norbixin-based PHB membrane led to control of the inflammatory process. However, it did not favor fibroblast proliferation and did not optimize type I collagen formation in the expected stage of the repair process.
Collapse
|